Immunotherapy in malignant peritoneal mesothelioma (Review)
- Authors:
- Sabah Alaklabi
- Arya Mariam Roy
- Joseph J. Skitzki
- Renuka Iyer
-
Affiliations: Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA, Department of Surgical Oncology/Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA - Published online on: February 22, 2023 https://doi.org/10.3892/mco.2023.2627
- Article Number: 31
This article is mentioned in:
Abstract
|
Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac LR, et al: Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 137:647–667. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Bridda A, Padoan I, Mencarelli R and Frego M: Peritoneal mesothelioma: A review. MedGenMed. 9(32)2007.PubMed/NCBI | |
|
Teta MJ, Mink PJ, Lau E, Sceurman BK and Foster ED: US mesothelioma patterns 1973-2002: Indicators of change and insights into background rates. Eur J Cancer Prev. 17:525–534. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Selikoff IJ, Hammond EC and Seidman H: Latency of asbestos disease among insulation workers in the United States and Canada. Cancer. 46:2736–2740. 1980.PubMed/NCBI View Article : Google Scholar | |
|
Moolgavkar SH, Meza R and Turim J: Pleural and peritoneal mesotheliomas in SEER: Age effects and temporal trends, 1973-2005. Cancer Causes Control. 20:935–944. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, et al: The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 10:1243–1260. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Beebe-Dimmer JL, Fryzek JP, Yee CL, Dalvi TB, Garabrant DH, Schwartz AG and Gadgeel S: Mesothelioma in the United States: A surveillance, epidemiology, and end results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol. 8:743–750. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Ullah A, Waheed A, Khan J, Mishra A, Tareen B, Nama N, Karki NR, Panezai MS, Zarate LV, White J, et al: Incidence, survival analysis and future perspective of primary peritoneal mesothelioma (PPM): A population-based study from SEER Database. Cancers (Basel). 14(942)2022.PubMed/NCBI View Article : Google Scholar | |
|
Kaya H, Sezgı C, Tanrıkulu AC, Taylan M, Abakay O, Sen HS, Abakay A, Kucukoner M and Kapan M: Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma. Neoplasma. 61:433–438. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Antman KH: Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol. 8:313–320. 1981.PubMed/NCBI | |
|
Sugarbaker PH: Update on the management of malignant peritoneal mesothelioma. Transl Lung Cancer Res. 7:599–608. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Turaga KK, Deraco M and Alexander HR: Current management strategies for peritoneal mesothelioma. Int J Hyperthermia. 33:579–581. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Gazivoda VP, Kangas-Dick AW, Greenbaum AA, Roshal J, Chen C, Moore DF, Langan RC, Kennedy TJ, Minerowicz C and Alexander HR: Expression of PD-L1 in patients with malignant peritoneal mesothelioma: A pilot study. J Surg Res. 277:131–137. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Judge S, Thomas P, Govindarajan V, Sharma P and Loggie B: Malignant Peritoneal Mesothelioma: Characterization of the inflammatory response in the tumor microenvironment. Ann Surg Oncol. 23:1496–1500. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Tazzari M, Brich S, Tuccitto A, Bozzi F, Beretta V, Spagnuolo RD, Negri T, Stacchiotti S, Deraco M, Baratti D, et al: Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of adaptive immunological signature in the more aggressive histological types. J Immunol Res. 2018(5804230)2018.PubMed/NCBI View Article : Google Scholar | |
|
Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T and Deftereos G: Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. Hum Pathol. 87:11–17. 2019.PubMed/NCBI View Article : Google Scholar | |
|
White MG, Schulte JJ, Xue L, Berger Y, Schuitevoerder D, Vining CC, Kindler HL, Husain A, Turaga KK and Eng OS: Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br J Cancer. 124:564–566. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 372:2509–2520. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Palmieri G, Colombino M, Cossu A, Marchetti A, Botti G and Ascierto PA: Genetic instability and increased mutational load: Which diagnostic tool best direct patients with cancer to immunotherapy? J Transl Med. 15(17)2017.PubMed/NCBI View Article : Google Scholar | |
|
Jamieson NB and Maker AV: Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Ther. 24:134–140. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, et al: Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9(34)2017.PubMed/NCBI View Article : Google Scholar | |
|
Chang L, Chang M, Chang HM and Chang F: Microsatellite instability: A predictive biomarker for cancer immunotherapy. Appl Immunohistochem Mol Morphol. 26:e15–e21. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 357:409–413. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz H-J, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al: Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol. 18:1182–1191. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, et al: Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 36:773–779. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Imai K and Yamamoto H: Carcinogenesis and microsatellite instability: The interrelationship between genetics and epigenetics. Carcinogenesis. 29:673–680. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Watson P and Lynch HT: The tumor spectrum in HNPCC. Anticancer Res. 14 (4B):1635–1639. 1994.PubMed/NCBI | |
|
Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, Reeser JW, Yu L and Roychowdhury S: Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017(PO.17.00073)2017.PubMed/NCBI View Article : Google Scholar | |
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 348:124–128. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, et al: Targeted next generation sequencing identifies markers of response to PD-1 Blockade. Cancer Immunol Res. 4:959–967. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Shao C, Li G, Huang L, Pruitt S, Castellanos E, Frampton G, Carson KR, Snow T, Singal G, Fabrizio D, et al: Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors. JAMA Netw Open. 3(e2025109)2020.PubMed/NCBI View Article : Google Scholar | |
|
Yamada N, Oizumi S, Kikuchi E, Shinagawa N, Konishi-Sakakibara J, Ishimine A, Aoe K, Gemba K, Kishimoto T, Torigoe T and Nishimura M: CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother. 59:1543–1549. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Anraku M, Cunningham KS, Yun Z, Tsao MS, Zhang L, Keshavjee S, Johnston MR and de Perrot M: Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 135:823–829. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Thapa B, Walkeiwicz M, Rivalland G, Murone C, Asadi K, Barnett S, Knight S, Hendry S, Russell P and John T: OA08.05 quantifying tumour infiltrating lymphocytes (TILs) in malignant pleural mesothelioma (MPM)-defining the hot, the warm and the cold tumours. J Thorac Oncol. 13(S339)2018. | |
|
Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, et al: Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol. 232:199–209. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Brustugun OT, Helland A, Lund-Iversen M, et al: Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Ann Oncol. 27:225–232. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, et al: Assessing tumor-infiltrating lymphocytes in solid tumors: A practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol. 24:235–251. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT and Gajewski TF: Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 5(200ra116)2013.PubMed/NCBI View Article : Google Scholar | |
|
Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC and Lambrecht BN: Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J. 27:1086–1095. 2006.PubMed/NCBI View Article : Google Scholar | |
|
DeLong P, Carroll RG, Henry AC, Tanaka T, Ahmad S, Leibowitz MS, Sterman DH, June CH, Albelda SM and Vonderheide RH: Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther. 4:342–346. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Meloni F, Morosini M, Solari N, Passadore I, Nascimbene C, Novo M, Ferrari M, Cosentino M, Marino F, Pozzi E and Fietta AM: Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol. 67:1–12. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Kojima M, Kajino K, Momose S, Wali N, Hlaing MT, Han B, Yue L, Abe M, Fujii T, Ikeda K and Hino O: Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression. Respir Res. 21(187)2020.PubMed/NCBI View Article : Google Scholar | |
|
Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Brabletz T, Kalluri R, Nieto MA and Weinberg RA: EMT in cancer. Nat Rev Cancer. 18:128–134. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Aiello NM and Kang Y: Context-dependent EMT programs in cancer metastasis. J Exp Med. 216:1016–1026. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Dongre A and Weinberg RA: New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 20:69–84. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, Thiery JP and Chouaib S: New insights into the role of EMT in tumor immune escape. Mol Oncol. 11:824–846. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Taki M, Abiko K, Ukita M, Murakami R, Yamanoi K, Yamaguchi K, Hamanishi J, Baba T, Matsumura N and Mandai M: Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition. Clin Cancer Res. 27:4669–4679. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Salazar Y, Zheng X, Brunn D, Raifer H, Picard F, Zhang Y, Winter H, Guenther S, Weigert A, Weigmann B, et al: Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer. J Clin Invest. 130:3560–3575. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, Armenoult L, Montagne F, Tranchant R, Renier A, et al: Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat Commun. 10(1333)2019.PubMed/NCBI View Article : Google Scholar | |
|
Wu L, Amjad S, Yun H, Mani S and de Perrot M: A panel of emerging EMT genes identified in malignant mesothelioma. Sci Rep. 12(1007)2022.PubMed/NCBI View Article : Google Scholar | |
|
Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, et al: Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma. Cancer Discov. 11:2738–2747. 2021.PubMed/NCBI View Article : Google Scholar | |
|
de Reyniès A, Jaurand MC, Renier A, Couchy G, Hysi I, Elarouci N, Galateau-Sallé F, Copin MC, Hofman P, Cazes A, et al: Molecular classification of malignant pleural mesothelioma: Identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res. 20:1323–1334. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, Yang H and Carbone M: Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 36:76–81. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Kaszuba MC, Pulido JS, Folpe AL, Pichurin PN, Goodenberger ML and Spinner RJ: Malignant peripheral nerve sheath tumor in a Patient with BAP1 tumor predisposition syndrome. World Neurosurg. 109:362–364. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, Adomat HH, Lin D, Xue H, Dong X, et al: BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Med. 11(8)2019.PubMed/NCBI View Article : Google Scholar | |
|
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Taylor L, Ashland J, Ye Z, et al: Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: Outcomes of an expanded access program. Clin Lung Cancer. 7:40–46. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, Liu Y, Blatter J, Visseren-Grul C and Stahel R: Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 64:211–218. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, et al: Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 19:370–373. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, et al: Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 24:1443–1448. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, et al: Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: Results of the International Expanded Access Program. J Thorac Oncol. 3:756–763. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, et al: Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet. 387:1405–1414. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen FL, Delord JP, Dowlati A, Kochuparambil ST, Taylor MH, et al: Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: Phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 5:351–357. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, et al: Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): A multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 22:1530–1540. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O'Brien M, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, et al: A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: The European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol. 31:1734–1745. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Maio M, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, et al: Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 18:1261–1273. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Desai A, Karrison T, Rose B, Pemberton E, Hill B, Straus CM, Tan Y-HC, Seiwert TY and Kindler HL: Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM). J Clin Oncol. 36 (Suppl 15)(S8565)2018. | |
|
Marmarelis ME, Wang X, Roshkovan L, Walker S, McNulty S, Ciunci CA, Muira J, Katz SI, Cengel KA, et al: Real-world outcomes of pembrolizumab in peritoneal mesothelioma. J Clin Oncol. 38 (Suppl 15)(e21094)2020. | |
|
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, et al: First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 33:488–499. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Calabrò L, Rossi G, Morra A, Rosati C, Cutaia O, Daffinà MG, Altomonte M, Di Giacomo AM, Casula M, Fazio C, et al: Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: A follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. Lancet Respir Med. 9:969–976. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Calabrò L, Morra A, Giannarelli D, Amato G, D'Incecco A, Covre A, Lewis A, Rebelatto MC, Danielli R, Altomonte M, et al: Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): An open-label, non-randomised, phase 2 study. Lancet Respir Med. 6:451–460. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Raghav K, Liu S, Overman M, Morani A, Willette A, Fournier K and Varadhachary G: Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma. JAMA Netw Open. 4(e2119934)2021.PubMed/NCBI View Article : Google Scholar | |
|
Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, Purcell T, Santana-Davila R, Dudek AZ, Borghaei H, et al: Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: Survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 27:1910–1920. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Foote MB, Shia J, Zauderer MG, Nash GM and Cercek A: Treatment of platinum nonresponsive metastatic malignant peritoneal mesothelioma with combination chemoimmunotherapy. J Immunother. 45:100–103. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, et al: Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): A double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 7:569–580. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Bijelic L, Darcy K, Stodghill J, Tian C and Cannon T: Predictors and outcomes of surgery in peritoneal mesothelioma: An analysis of 2000 patients from the National cancer database. Ann Surg Oncol. 27:2974–2982. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Thompson JC, Hwang WT, Davis C, Deshpande C, Jeffries S, Rajpurohit Y, Krishna V, Smirnov D, Verona R, Lorenzi MV, et al: Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Lung Cancer. 139:1–8. 2020.PubMed/NCBI View Article : Google Scholar | |
|
de Boer NL, van Kooten JP, Burger JWA, Verhoef C, Aerts JGJV and Madsen EVE: Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: Rationale and design of the MESOPEC trial. BMJ Open. 9(e026779)2019.PubMed/NCBI View Article : Google Scholar | |
|
Adusumilli PS, Zauderer MG, Rivière I, Solomon SB, Rusch VW, O'Cearbhaill RE, Zhu A, Cheema W, Chintala NK, Halton E, et al: A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti-PD-1 Agent Pembrolizumab. Cancer Discov. 11:2748–2763. 2021.PubMed/NCBI View Article : Google Scholar |
